Apotex Health (TSX:APTX) Stock Hit By Revenue Drop And Profit Reversal

Apotex Health walked into this earnings day with the stock down about 5% over the past week and 6% over the past month, so expectations were already muted. The headline today is a sharp profit squeeze. Revenue for Q1 2027 came in at about CA$848 million while the company swung from a profit of CA$362.7 million a year ago to a net loss of CA$38.3 million.

That kind of reversal hits investor confidence hard, especially in a pharmaceutical business where margin stability is closely watched. The market now has to decide whether this loss is a one off blip or the start of a tougher earnings phase for Apotex Health.

Looking for steadier options in healthcare after Apotex Health's shift from profit to loss? Check out our list of list of solid balance sheet and fundamentals stocks (12 results)

Q1 2027 Earnings Summary

• Revenue Q1 2027: CA$847.98 million vs. Q1 2026 CA$1,142.29 million (revenue declined by about 25.8%)
• Net Income/Loss Q1 2027: loss of CA$38.35 million vs. Q1 2026 profit of CA$362.70 million (moved from profit to loss)
• Basic EPS Q1 2027: loss of CA$0.19 per share vs. Q1 2026 earnings of CA$1.88 per share (moved from earnings to loss)
• Trailing 12 Month Revenue to Q1 2027: CA$3.20b vs. trailing 12 months to Q4 2026 CA$3.49b (revenue declined by about 8.4%)

Prefer clear charts to a dense wall of earnings figures and commentary? Explore Apotex Health's full financial picture, including a visual breakdown of its recent profitability shift, in our company report for Apotex Health.

Apotex Health bull case hinges on profit quality

The upbeat story around Apotex Health as a diversified pharma platform leans on Canada and new launches. Canada grew double digits and adjusted EBITDA margin held around 31%, which fits a resilience narrative in the core business. Launches like semaglutide in Canada and Infuvite in the U.S. point to useful new revenue legs. The reported swing to a CA$38.3m loss, driven largely by non cash share based compensation and FX, keeps the focus on underlying earnings quality rather than a simple profit collapse.

Profit squeeze reinforces near term bear arguments

The bearish angle finds support in the sharp reported move from a CA$362.7m profit a year ago to a CA$38.3m loss, plus revenue falling to about CA$848m from CA$1.14b. That undercuts any simple “steady compounder” story for Apotex Health. U.S. revenue pressure, product pauses and a drop in adjusted net income despite new launches all point to a business still working through competitive and operational headwinds, even with lower net debt and an investment grade rating in place.

After sharp swings in reported earnings and pressure in U.S. operations, are investors seeing the full picture of Apotex Health's vulnerabilities? Review our risk analysis for Apotex Health which shows 1 important warning sign

Stay Ahead Of Your Next Move

Apotex Health's shift from profit to loss can create uncertainty, so register for free with Simply Wall St and add it to a Watchlist to track how its share price lines up against fair value and identify a potential entry that fits your view. Once you hold the stock, use the Portfolio Command Center to cut through noise and focus on the key developments that matter for your returns. For a longer term view, tap into crowd insights and different angles on Apotex Health through the Community. By surfacing potential catalysts and risks early, you may be able to react quickly and stay ahead of the market.

Seeking Alternatives Beyond Apotex Health?

Fresh ideas can move quickly once momentum builds. Spot potential breakouts while they are still under the radar for now and before the crowd catches on. Act now.

• Scan for stocks with strong price and earnings momentum that may be building toward their next breakout by reviewing the curated list of 74 profitable AI stocks that aren't just burning cash
• Secure potential income streams from companies targeting durable payouts and growing cash flows by checking the hand picked group of 5 dividend fortresses
• Hunt for businesses with sturdy finances that could hold up when others wobble by using the carefully filtered 7 resilient stocks with low risk scores

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com